A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E

Total Page:16

File Type:pdf, Size:1020Kb

A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible. iii TABLE OF CONTENTS LIST OF FIGURES iv LIST OF TABLES vi CHAPTER 1. INTRODUCTI ON 1 CHAPTER 2. LITERATURE REVIEW 2 CHAPTER 3. METHOD S AND MATERIALS 19 CHAPTER 4. RESULTS 26 CHAPTER 5. SUMMARY AND INTERPRETATION 53 CHAPTER 6. CONCLUSIONS 55 APPENDIX : COMPOUND STRUCTURES 56 REFERENCES CITED 61 ACKNOWLEDGEMENTS 67 iv LIST OF FIGURES Figure 1. Chemical structure of cortisol with steroid numbering system 2 Figure 2. Route from cholesterol to cortisol 4 Figure 3. Dexamethasone and b etameth asone with major metabolites 6 Figure 4. Illustration of electron impact for molecule ABC 12 Figure 5. Diagram of chemical ionization reactions 13 Figure 6. Total Ion chromatograph of 100 ng/ml standard in cani ne urine 32 Figure 7. Ion c hromatograph using filters for c ortisone and hydrocortisone 33 Figure 8. Ion chromatograph and mass spectra of cortisone and hydrocortisone 34 Figure 9. Chromatograph and mass spectra of dexamethasone and betamethasone 35 Figure 10 . pH vs. drug recovery for first set of analytes (100 ng/ml) in equine plasma. 39 Figure 11 . pH vs. drug recovery for second set of analytes (100 ng/ml) in equine plasma. 39 Figure 12. pH vs. drug reco very for third set of analytes (100 ng/ml) in equine plasma. 40 Figure 13. Extracted dexamethasone calibration curve in canine urine. 40 Figure 14. Dexamethasone elimination study area counts vs. hours post dose 43 Figure 15. De xamethasone elimination study results last 48 hours on smaller scale 43 Figure 16. Dexamethasone elimination study concen trations vs. hours post dose 44 Figure 17. Hydrocortisone concentration in equine dexamethasone study 46 Figure 18. Cortisone concentration in dexamethasone equine urine study 47 Figure 1 9. Dexamethasone concentration in dexamethasone equine urine study 47 Figure 20 . Comparison of dexamethasone concentration to cortisone and hydrocortisone 48 Figure 21 . Chromatograph and mass spectra of fludrocortisone metabolite 50 Figure 2 2. Chromatographs of fludrocortisone and metabolite 51 Figure 23. Chemical structure of fludrocortisone 51 Figure 24. P roposed c hemical stru cture of fludrocortisone metabolite 52 v Figure 25. Structures of amcinonide through cortisone 56 Figure 26. S tructures of deoxycorticosterone to flumethasone 57 Figure 27. S tructures of fluocinolone acetamide to medrysone 58 Figure 28. S tructure s of methyprednisolone to prednisone 59 Figure 29. S tructures of triamicinolone and triamicinolone acetomide 60 vi LIST OF TABLES Table 1. List of various endogenous and exogenous glucocorticoids 8 Table 2. HPLC gradient with m obile phase composition gradient 24 Table 3. Ions and retention times (RT) using LC/MSn 26 Table 4. Mass spectrometer tune parameters 28 Table 5. Extraction recoveries of select analytes in canine urine at various pH levels 35 Table 6. Average recoveries and R 2 of standards 0.5 - 200ng/ml in stripped canine urine 36 Table 7. Extraction recoveries of select analytes in stripped equine plasma at varying pH levels at 100 ng/m l 37 Table 8. Canine urine volume and pH value in dexam ethasone study 41 Table 9. Dexamethasone in canine urine results 42 Table 10 . Hydrocortisone in equine urine dexamethasone study 44 Table 11. Cortisone in equine urine dexamethasone study 45 Table 12. Dexamethasone in equine urine study 45 Table 1 3. Calibration curve in fludrocortisone canine urine study 48 Table 1 4. Fludrocortisone for run s 1 -3 in canine urine 49 Table 1 5. Hydrocortisone in fludrocortisone canine urine study 49 Table 1 6. Cortiso ne in fludrocortisone canine urine st udy 49 Table 1 7. Fludrocortisone metabolite areas in canine urine 50 1 CHAPTER 1. INTRODUCTION Gluc oco rticosteroids are a class of steroids that have been used to obtain beneficial and detrimental resul ts in the horse and dog racing industry. Gluc oco rticosteroids , also known as glucocorticoids, are used to treat inflammation in horses and dogs that have been stressed or injured to allow the animals to return to the racing circuit more quickly than natur al ly . While these treatments, when used correctly , wou ld bene fit th e animal just as anti -inflamma tories benefit humans, they can also cause detrimental effects to the health of the animal. Glucocorticoids are a key ingredient in maintaining homeostasi s in the body . This homeostasis is affected by t rauma, exercise and cold that increas e production of the corticotrop in releasing factor in the hypothalamus (Wilke et al 1982) . The corticotropin releasing factor increases the production of glucocorticoids (Wilke et al 1982 ). There are two reasons for interest in the ability to detect glu cocorticoids in racing animals. First, glucocorticoid residuals in the animal are undesirable in the racing industry as the residuals can be evidence of dosing the anima l. Since these chemicals decreas e the amount of pain the animal experien ces, the animal may increase trauma due to lack of feedback. The decreased pain may be a result of reduced pressure on the nerves due to less inflammation but the exact reason is un clear (Martindale, 2005). The second reason is that the treatment with gluco co rticoids can affect performance that could affect the outcome of the pari -mutuel races. Par i-mutuel racing, dogs and horses, generated over $4 billion in revenues and receipts in the United States in 2002 (U.S. Census Bureau 2002 ). This paper presents research to characterize and quantify glucocorticoi ds in equine urine and plasma and in canine urine. This paper also summarizes an elimination study of an under -examined glucocor ticoid. The research incorporates a liquid \liquid extraction from a small aliquot of sample. This aliquot is analyzed for many glucocorticoids in a single liquid chromatography mass spectrometry run. 2 CHAPTER 2. LITERATURE REVIEW Cortisol (hydrocortison e) is the principal glucocorticoid in horse and dog blood and also the most potent naturally produced corticosteroid ( Gower , 1984) . Cortisol is produced by the adrenal gland, decreases the body’s response to stress, decreases inflammation, and can cause e uphoria. One study states the no rmal range in horses to be 50 -3500 nmol/L (Irvine et al 1988) . Cortisol maintains homeostasis in the body . I ntroduction of compounds that mimic cortisol decrease s cortisol production (Toutain et al , 1984) . Synthesis : “The adrenal cortex produces corticosteroids which are a group of C 21 steroids” (Gallciano , 1985) . “This group known as 4 -en -3-ones contains a double bond at C-4 and an oxo group at C -3. These compounds also have a side chain at C -17 and may or may not co ntain a hydroxyl group. The 17 - hydroxylated glucocorticoids are more powerful than the non -hydroxylated count erparts. There is hydroxyl at C -21 and an oxo group at C -20. ” “There also needs to be an oxygen function, hydroxyl or oxo group which may or ma y not be at C -11” (Gower , 1984) . Th e steroid numbering system is illustrated using cortisol in figure 1. Figure 1 . Chemical structure of c ortisol with steroid numbering system (Wilke , 1982) 3 Effects: Gower (1984) stated corticosteroids increase blood glucose level by promoting the hepatic conversion of a mino acids to glucose. These compounds also oppose insulin in allowing glucose into adipose cells, which in effect mobilizes fat and releases free fatty acids to the liver. Corticosteroids cause a net reduction in protein synthesis in muscle and lymphatic tissue , which reduces antibody synthesis. This net protein loss is due to increased protein catabolism (Martindale, 2005). Deluca (1984) stated g lucocorticoids also suppress intestinal calcium absor ption therefore lowering plasma calcium levels. Lower plasma calcium levels can l ead to bone decalcification. Corticosteroids counteract the histamine and serotonin effects of increased capillary permeability and dilation which are part of the inflammato ry response. This increase d capillary resistance reduces the movement of leucocytes to the site of infection. Therefore, phagocytosis decreases (Gower , 1984) . These chemicals can also cause adrenal gland atrophy (Ralston and Stenhouse, 1990).
Recommended publications
  • Trihydroxyisoflavone Improves Skin Barrier Function Impaired by E
    www.nature.com/scientificreports OPEN A novel mineralocorticoid receptor antagonist, 7,3’,4’‑trihydroxyisofavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids Hanil Lee1,5, Eun‑Jeong Choi2,5, Eun Jung Kim1, Eui Dong Son2, Hyoung‑June Kim2, Won‑Seok Park2, Young‑Gyu Kang2, Kyong‑Oh Shin3, Kyungho Park3, Jin‑Chul Kim4, Su‑Nam Kim4 & Eung Ho Choi1* Excess glucocorticoids (GCs) with either endogenous or exogenous origins deteriorate skin barrier function. GCs bind to mineralocorticoid and GC receptors (MRs and GRs) in normal human epidermal keratinocytes (NHEKs). Inappropriate MR activation by GCs mediates various GC‑induced cutaneous adverse events. We examined whether MR antagonists can ameliorate GC‑mediated skin barrier dysfunction in NHEKs, reconstructed human epidermis (RHE), and subjects under psychological stress (PS). In a preliminary clinical investigation, topical MR antagonists improved skin barrier function in topical GC‑treated subjects. In NHEKs, cortisol induced nuclear translocation of GR and MR, and GR and MR antagonists inhibited cortisol‑induced reductions of keratinocyte diferentiation. We identifed 7,3’,4’‑trihydroxyisofavone (7,3’,4’‑THIF) as a novel compound that inhibits MR transcriptional activity by screening 30 cosmetic compounds. 7,3’,4’‑THIF ameliorated the cortisol efect which decreases keratinocyte diferentiation in NHEKs and RHE. In a clinical study on PS subjects, 7,3’,4’‑ THIF (0.1%)‑containing cream improved skin barrier function, including skin surface pH, barrier recovery rate, and stratum corneum lipids. In conclusion, skin barrier dysfunction owing to excess GC is mediated by MR and GR; thus, it could be prevented by treatment with MR antagonists. Therefore, topical MR antagonists are a promising therapeutic option for skin barrier dysfunction after topical GC treatment or PS.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Do Intra-Articular Steroid Injections Affect Glycemic Control in Patients
    Evidence-based answers from the Family Physicians Inquiries Network Erin Kallock, MD; Do intra-articular steroid Jon O. Neher, MD Valley Family Medicine Residency, Renton, Wash. injections aff ect glycemic control Leilani St. Anna, MLIS, AHIP University of Washington in patients with diabetes? Health Services Library, Seattle EVIDENCE-BASED ANSWER yes, but the clinical importance mendation [SOR]: B, small cohort studies). A is minimal. A single intra-articular Intra-articular steroid injections into the steroid injection into the knee produces shoulder may briefl y raise postprandial (but acute hyperglycemia for 2 or 3 days in pa- not mean) glucose levels with larger and re- tients with diabetes who otherwise have peated doses (SOR: C, extrapolated from het- good glucose control (strength of recom- erogenous and mixed cohort studies). A single steroid injection into the knee joint Evidence summary 1 week; investigators measured fructosamine causes acute Two prospective cohort studies evaluated the levels (a measure of intermediate-term hyperglycemia eff ect on glycemic control of a single gluco- glucose control) at baseline and again for 2 or 3 days corticoid injection into the knee of patients 2 weeks after injection. in patients with with controlled type 2 diabetes (glycosylated Th e injection produced hyperglycemia in diabetes who hemoglobin A1c Ͻ7.0%). Th e fi rst enrolled all participants, with peak blood glucose lev- otherwise have 9 patients with symptomatic osteoarthritis of els ranging from 251 to 430 mg/dL and time to good glucose the knee unresponsive to 3 months of nonste- peak glucose usually less than 6 hours. Fruc- control.
    [Show full text]
  • Clinical Policy: Topical Agents: Corticosteroids
    Clinical Policy: Topical Agents: Corticosteroids Reference Number: OH.PHAR.PPA.92 Effective Date: 01/01/2020 Revision Log Last Review Date: Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description TOPICAL AGENTS: CORTICOSTEROIDS – LOW POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON- PREFERRED” DESONIDE cream, ointment (generic of Desowen®) ALCLOMETASONE cream, ointment (generic of FLUOCINOLONE ACETONIDE 0.01% cream, solution Aclovate®) (generic of Synalar®) CAPEX® shampoo (fluocinolone acetonide) FLUOCINOLONE body oil, scalp oil (generic of Derma- DESONATE®gel (desonide) Smoothe/ FS®) DESONIDE lotion (generic of Desowen®) HYDROCORTISONE cream, lotion, ointment HYDROCORTISONE ACETATE WITH ALOE gel HYDROCORTISONE WITH UREA cream (generic of Carmol HC®) PANDEL® cream (hydrocortisone probutate) PEDIADERM HC® kit TOPICAL AGENTS: CORTICOSTEROIDS – MEDIUM POTENCY NO PA REQUIRED “PREFERRED” PA REQUIRED “NON--PREFERRED” BETAMETHASONE DIPROPIONATE-CALCIPOTRIENE BETAMETHASONE DIPROPIONATE lotion (generic of Ointment Diprolene®) BETAMETHASONE VALERATE cream, lotion (generic of CLOCORTOLONE PIVALATE (generic of Cloderm®) Valisone®) CORDRAN® tape (flurandrenolide) FLUTICASONE PROPIONATE cream, ointment (generic of DESOXIMETASONE cream, gel, ointment (generic of Cutivate®) Topicort®) MOMETASONE FUROATE cream, ointment, solution FLUOCINOLONE ACETONIDE 0.025% cream, ointment (generic of Elocon®) (generic of Synalar®) PREDNICARBATE cream (generic of Dermatop®) FLUTICASONE
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Formulary Updates Effective January 1, 2021
    Formulary Updates Effective January 1, 2021 Dear Valued Client, Please see the following lists of formulary updates that will apply to the HometownRx Formulary effective January 1 st , 2021. As the competition among clinically similar products increases, our formulary strategy enables us to prefer safe, proven medication alternatives and lower costs without negatively impacting member choice or access. Please note: Not all drugs listed may be covered under your prescription drug benefit. Certain drugs may have specific restrictions or special copay requirements depending on your plan. The formulary alternatives listed are examples of selected alternatives that are on the formulary. Other alternatives may be available. Members on a medication that will no longer be covered may want to talk to their healthcare providers about other options. Medications that do not have alternatives will be available at 100% member coinsurance . Preferred to Non -Preferred Tier Drug Disease State /Drug Class Preferred Alternatives ALREX Eye inflammation loteprednol (generic for LOTEMAX) APRISO 1 Gastrointestinal agent mesalamine (generic for APRISO) BEPREVE Eye allergies azelastine (generic for OPTIVAR) CIPRODEX 1 Ear inflammation ciprofloxacin-dexamethasone (generic for CIPRODEX) COLCRYS 1 Gout colchicine (generic for COLCRYS) FIRST -LANSOPRAZOLE Gastrointestinal agent Over-the-counter lansoprazole without a prescription FIRST -MOUTHWASH BLM Mouth inflammation lidocaine 2% viscous solution (XYLOCAINE) LOTEMAX 1 Eye inflammation loteprednol etabonate (generic
    [Show full text]
  • Australian Public Assessment Report for Clobetasol Propionate
    Australian Public Assessment Report for Clobetasol propionate Proprietary Product Name: Clobex Sponsor: Galderma Australia Pty Ltd May 2013 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and Ageing, and is responsible for regulating medicines and medical devices. • TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance), when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision-making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <http://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations, and extensions of indications. • An AusPAR is a static document, in that it will provide information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]